Immix Biopharma Gets Orphan Drug Label in Europe For Multiple Myeloma Treatment
Immix Biopharma (IMMX) said Monday that the European Commission has granted orphan drug designation to NXC-201 for the treatment of multiple myeloma. The designation qualifies NXC-201 among others for
MT NewswiresApr 29 14:50 ET
Express News | Immix Biopharma Awarded European Union Orphan Drug Designation for Nxc-201 in Multiple Myeloma
ReutersApr 29 09:39 ET
Immix Biopharma on Track to Dose First Patients With AL Amyloidosis Therapy by Mid-Year
Immix Biopharma (IMMX) Thursday said it is on track to dose first patients with relapsed or refractory AL Amyloidosis with its CAR-T NXC-201 therapy candidate by mid-2024 after scheduling initiation v
MT NewswiresApr 18 16:12 ET
Immix Biopharma on Track to Dose NXC-201 Patients in United States
Scheduling U.S. site initiation visits April and May 2024On track to dose relapsed/refractory AL Amyloidosis patients with CAR-T NXC-201 at New York City lead site and other leading U.S. sites mid-2024 No
GlobeNewswireApr 18 09:32 ET
Express News | Immix Biopharma Announces Late-Breaking Nxc-201 Clinical Data Abstract Accepted for Oral Presentation at the 27TH Annual Meeting of the American Society of Gene and Cell Therapy (Asgct)
Moomoo 24/7Apr 15 09:36 ET
Express News | Immix Biopharma Announces Comprehensive Cancer Center As Lead Site For NXC-201 AL Amyloidosis Clinical Trial
Moomoo 24/7Mar 20 09:52 ET
Immix Biopharma Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 AL Amyloidosis Clinical Trial
LOS ANGELES, CA, March 20, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (NASDAQ:IMMX) ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL
GlobeNewswireMar 20 09:46 ET
Immix Biopharma Announces 12-Month Progress Update Including Shareholder Letter
Immix Biopharma, Inc. (NASDAQ:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced its 12-month progress update including shareholder le
BenzingaFeb 21 09:39 ET
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
LOS ANGELES, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company pioneering personalized therapies for oncology and
GlobeNewswireFeb 8 16:45 ET
Immix Biopharma Awarded European Union Orphan Drug Designation For NXC-201 In AL Amyloidosis
European Orphan Drug Designation ("ODD") qualifies NXC-201 for:10 years of market exclusivity once authorized in the EUAccess to the EU centralized authorization procedureReduced fees for EU protocol
BenzingaFeb 7 09:41 ET
Immix Biopharma Announces New Offering, Sparks Investor Interest
TipRanksFeb 7 04:22 ET
Immix Biopharma Signs Definitive $15M Titan Partnership Deal
TipRanksFeb 7 04:22 ET
PRSO, AKRO and MIRA Among Pre-market Losers
Seeking AlphaFeb 6 08:37 ET
Immix Biopharma Suspends Stock Offering Pending New Prospectus
TipRanksFeb 6 04:57 ET
Immix Biopharma Prices $15 Million Stock Offering
Immix Biopharma (IMMX) said late Monday it priced an underwritten public offering of approximately 5.5 million shares of common stock at $2.71 per share for expected gross proceeds of $15 million. The
MT NewswiresFeb 6 04:44 ET
Immix Is a Clinical-Stage Biopharmaceutical Co Developing Cell Therapies in Autoimmune Disease >IMMX
Immix Is a Clinical-Stage Biopharmaceutical Co Developing Cell Therapies in Autoimmune Disease >IMMX
Dow JonesFeb 5 22:56 ET
Immix Biopharma: Titan Partners Group, a Division of American Capital Partners, Is Sole Bookrunning Manager for Offering >IMMX
Immix Biopharma: Titan Partners Group, a Division of American Capital Partners, Is Sole Bookrunning Manager for Offering >IMMX
Dow JonesFeb 5 22:56 ET
Immix Biopharma Plans to Use Net Proceeds From Offering for NXC-201 Clinical Trials, Working Capital, General Purposes >IMMX
Immix Biopharma Plans to Use Net Proceeds From Offering for NXC-201 Clinical Trials, Working Capital, General Purposes >IMMX
Dow JonesFeb 5 22:55 ET
Immix Biopharma Expects Gross Proceeds of About $15M From Offering >IMMX
Immix Biopharma Expects Gross Proceeds of About $15M From Offering >IMMX
Dow JonesFeb 5 22:53 ET
Immix Biopharma Prices Public Offering of 5.5M Shares at $2.71 Each >IMMX
Immix Biopharma Prices Public Offering of 5.5M Shares at $2.71 Each >IMMX
Dow JonesFeb 5 22:52 ET
No Data
No Data